2,895 Shares in Edwards Lifesciences Corporation (EW) Acquired by Lombard Odier Asset Management Europe Ltd, Report finds

2,895 Shares in Edwards Lifesciences Corporation (EW) Acquired by Lombard Odier Asset Management Europe Ltd, Report finds

Lombard Odier Asset Management Europe Ltd bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the third quarter, Holdings Channel reports. The firm bought 2,895 shares of the medical research company’s stock, valued at approximately $349,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of EW. Huntington National Bank raised its stake in Edwards Lifesciences Corporation by 56.9% in the second quarter. Huntington National Bank now owns 5,015 shares of the medical research company’s stock valued at $500,000 after buying an additional 1,819 shares in the last quarter. Emerald Advisers Inc. PA acquired a new stake in Edwards Lifesciences Corporation during the second quarter valued at approximately $817,000. Quantitative Systematic Strategies LLC raised its stake in Edwards Lifesciences Corporation by 184.3% in the second quarter. Quantitative Systematic Strategies LLC now owns 8,523 shares of the medical research company’s stock valued at $826,000 after buying an additional 5,525 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD raised its stake in Edwards Lifesciences Corporation by 1.4% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 16,522 shares of the medical research company’s stock valued at $1,647,000 after buying an additional 223 shares in the last quarter. Finally, BP PLC raised its stake in Edwards Lifesciences Corporation by 22.0% in the second quarter. BP PLC now owns 50,000 shares of the medical research company’s stock valued at $4,987,000 after buying an additional 9,000 shares in the last quarter. Institutional investors own 82.89% of the company’s stock.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up 0.13% during mid-day trading on Wednesday, reaching $90.83. 1,783,704 shares of the company traded hands. The stock’s 50 day moving average is $94.88 and its 200 day moving average is $103.37. The stock has a market capitalization of $19.41 billion, a PE ratio of 34.80 and a beta of 0.53. Edwards Lifesciences Corporation has a 52-week low of $76.90 and a 52-week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, February 1st. The medical research company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.03. The firm earned $767.70 million during the quarter, compared to analysts’ expectations of $760.85 million. Edwards Lifesciences Corporation had a net margin of 19.22% and a return on equity of 25.00%. The business’s quarterly revenue was up 14.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.64 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post $3.40 earnings per share for the current year.

Several analysts have recently commented on EW shares. BTIG Research reiterated a “buy” rating and issued a $110.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, October 28th. Royal Bank Of Canada decreased their target price on shares of Edwards Lifesciences Corporation from $130.00 to $123.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 26th. Stifel Nicolaus decreased their target price on shares of Edwards Lifesciences Corporation from $122.00 to $114.00 and set a “buy” rating on the stock in a research report on Wednesday, October 26th. Jefferies Group LLC restated a “buy” rating and set a $115.00 target price (down previously from $125.00) on shares of Edwards Lifesciences Corporation in a research report on Wednesday, October 26th. Finally, Canaccord Genuity set a $140.00 target price on shares of Edwards Lifesciences Corporation and gave the stock a “buy” rating in a research report on Tuesday, November 22nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. Edwards Lifesciences Corporation has an average rating of “Buy” and an average target price of $116.38.

In other news, VP Larry L. Wood sold 13,258 shares of the company’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $81.85, for a total value of $1,085,167.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 13,720 shares of the company’s stock in a transaction dated Thursday, January 12th. The stock was sold at an average price of $97.47, for a total transaction of $1,337,288.40. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 68,870 shares of company stock valued at $1,604,434 and have sold 187,928 shares valued at $17,001,801. 2.37% of the stock is owned by corporate insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Related posts

Leave a Comment

2,895 Shares in Edwards Lifesciences Corporation (EW) Acquired by Lombard Odier Asset Management Europe Ltd

2,895 Shares in Edwards Lifesciences Corporation (EW) Acquired by Lombard Odier Asset Management Europe Ltd

Lombard Odier Asset Management Europe Ltd bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the third quarter, Holdings Channel reports. The firm bought 2,895 shares of the medical research company’s stock, valued at approximately $349,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of EW. Huntington National Bank raised its stake in Edwards Lifesciences Corporation by 56.9% in the second quarter. Huntington National Bank now owns 5,015 shares of the medical research company’s stock valued at $500,000 after buying an additional 1,819 shares in the last quarter. Emerald Advisers Inc. PA acquired a new stake in Edwards Lifesciences Corporation during the second quarter valued at approximately $817,000. Quantitative Systematic Strategies LLC raised its stake in Edwards Lifesciences Corporation by 184.3% in the second quarter. Quantitative Systematic Strategies LLC now owns 8,523 shares of the medical research company’s stock valued at $826,000 after buying an additional 5,525 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD raised its stake in Edwards Lifesciences Corporation by 1.4% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 16,522 shares of the medical research company’s stock valued at $1,647,000 after buying an additional 223 shares in the last quarter. Finally, BP PLC raised its stake in Edwards Lifesciences Corporation by 22.0% in the second quarter. BP PLC now owns 50,000 shares of the medical research company’s stock valued at $4,987,000 after buying an additional 9,000 shares in the last quarter. Institutional investors own 82.89% of the company’s stock.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up 0.13% during mid-day trading on Wednesday, reaching $90.83. 1,783,704 shares of the company traded hands. The stock’s 50 day moving average is $94.88 and its 200 day moving average is $103.37. The stock has a market capitalization of $19.41 billion, a PE ratio of 34.80 and a beta of 0.53. Edwards Lifesciences Corporation has a 52-week low of $76.90 and a 52-week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, February 1st. The medical research company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.03. The firm earned $767.70 million during the quarter, compared to analysts’ expectations of $760.85 million. Edwards Lifesciences Corporation had a net margin of 19.22% and a return on equity of 25.00%. The business’s quarterly revenue was up 14.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.64 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post $3.40 earnings per share for the current year.

Several analysts have recently commented on EW shares. BTIG Research reiterated a “buy” rating and issued a $110.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, October 28th. Royal Bank Of Canada decreased their target price on shares of Edwards Lifesciences Corporation from $130.00 to $123.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 26th. Stifel Nicolaus decreased their target price on shares of Edwards Lifesciences Corporation from $122.00 to $114.00 and set a “buy” rating on the stock in a research report on Wednesday, October 26th. Jefferies Group LLC restated a “buy” rating and set a $115.00 target price (down previously from $125.00) on shares of Edwards Lifesciences Corporation in a research report on Wednesday, October 26th. Finally, Canaccord Genuity set a $140.00 target price on shares of Edwards Lifesciences Corporation and gave the stock a “buy” rating in a research report on Tuesday, November 22nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. Edwards Lifesciences Corporation has an average rating of “Buy” and an average target price of $116.38.

In other news, VP Larry L. Wood sold 13,258 shares of the company’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $81.85, for a total value of $1,085,167.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 13,720 shares of the company’s stock in a transaction dated Thursday, January 12th. The stock was sold at an average price of $97.47, for a total transaction of $1,337,288.40. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 68,870 shares of company stock valued at $1,604,434 and have sold 187,928 shares valued at $17,001,801. 2.37% of the stock is owned by corporate insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Related posts

Leave a Comment